Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 115

1.

Genetic Redirection of T Cells for the Treatment of Pancreatic Cancer.

Ali AI, Oliver AJ, Samiei T, Chan JD, Kershaw MH, Slaney CY.

Front Oncol. 2019 Feb 12;9:56. doi: 10.3389/fonc.2019.00056. eCollection 2019. Review.

2.

Multiplex immunohistochemistry accurately defines the immune context of metastatic melanoma.

Halse H, Colebatch AJ, Petrone P, Henderson MA, Mills JK, Snow H, Westwood JA, Sandhu S, Raleigh JM, Behren A, Cebon J, Darcy PK, Kershaw MH, McArthur GA, Gyorki DE, Neeson PJ.

Sci Rep. 2018 Jul 24;8(1):11158. doi: 10.1038/s41598-018-28944-3.

3.

Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4+Foxp3- Cell-Mediated Modulation of CD103+ Dendritic Cells.

Beavis PA, Henderson MA, Giuffrida L, Davenport AJ, Petley EV, House IG, Lai J, Sek K, Milenkovski N, John LB, Mardiana S, Slaney CY, Trapani JA, Loi S, Kershaw MH, Haynes NM, Darcy PK.

Cancer Immunol Res. 2018 Sep;6(9):1069-1081. doi: 10.1158/2326-6066.CIR-18-0291. Epub 2018 Jul 17.

4.

CARs versus BiTEs: A Comparison between T Cell-Redirection Strategies for Cancer Treatment.

Slaney CY, Wang P, Darcy PK, Kershaw MH.

Cancer Discov. 2018 Aug;8(8):924-934. doi: 10.1158/2159-8290.CD-18-0297. Epub 2018 Jul 16. Review.

5.

Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review.

Van Audenaerde JRM, Roeyen G, Darcy PK, Kershaw MH, Peeters M, Smits ELJ.

Pharmacol Ther. 2018 Sep;189:31-44. doi: 10.1016/j.pharmthera.2018.04.003. Epub 2018 Apr 13.

PMID:
29660367
6.

Bi-Allelic Mutations in STXBP2 Reveal a Complementary Role for STXBP1 in Cytotoxic Lymphocyte Killing.

Lopez JA, Noori T, Minson A, Li Jovanoska L, Thia K, Hildebrand MS, Akhlaghi H, Darcy PK, Kershaw MH, Brown NJ, Grigg A, Trapani JA, Voskoboinik I.

Front Immunol. 2018 Mar 15;9:529. doi: 10.3389/fimmu.2018.00529. eCollection 2018.

7.

Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses.

Oliver AJ, Lau PKH, Unsworth AS, Loi S, Darcy PK, Kershaw MH, Slaney CY.

Front Immunol. 2018 Jan 31;9:70. doi: 10.3389/fimmu.2018.00070. eCollection 2018. Review.

8.

Chimeric antigen receptor T cells form nonclassical and potent immune synapses driving rapid cytotoxicity.

Davenport AJ, Cross RS, Watson KA, Liao Y, Shi W, Prince HM, Beavis PA, Trapani JA, Kershaw MH, Ritchie DS, Darcy PK, Neeson PJ, Jenkins MR.

Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E2068-E2076. doi: 10.1073/pnas.1716266115. Epub 2018 Feb 12. Erratum in: Proc Natl Acad Sci U S A. 2019 May 28;116(22):11075-11076.

9.

An ultrastructural investigation of tumors undergoing regression mediated by immunotherapy.

Westwood JA, Ellis S, Danne J, Johnson C, Oorschot V, Ramm G, Tscharke DC, Davenport AJ, Whisstock JC, Darcy PK, Kershaw MH, Slaney CY.

Oncotarget. 2017 Dec 14;8(70):115215-115229. doi: 10.18632/oncotarget.23215. eCollection 2017 Dec 29.

10.

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer.

Dushyanthen S, Teo ZL, Caramia F, Savas P, Mintoff CP, Virassamy B, Henderson MA, Luen SJ, Mansour M, Kershaw MH, Trapani JA, Neeson PJ, Salgado R, McArthur GA, Balko JM, Beavis PA, Darcy PK, Loi S.

Nat Commun. 2017 Sep 19;8(1):606. doi: 10.1038/s41467-017-00728-9.

11.

Targeting the adenosine 2A receptor enhances chimeric antigen receptor T cell efficacy.

Beavis PA, Henderson MA, Giuffrida L, Mills JK, Sek K, Cross RS, Davenport AJ, John LB, Mardiana S, Slaney CY, Johnstone RW, Trapani JA, Stagg J, Loi S, Kats L, Gyorki D, Kershaw MH, Darcy PK.

J Clin Invest. 2017 Mar 1;127(3):929-941. doi: 10.1172/JCI89455. Epub 2017 Feb 6.

12.

A Multifunctional Role for Adjuvant Anti-4-1BB Therapy in Augmenting Antitumor Response by Chimeric Antigen Receptor T Cells.

Mardiana S, John LB, Henderson MA, Slaney CY, von Scheidt B, Giuffrida L, Davenport AJ, Trapani JA, Neeson PJ, Loi S, Haynes NM, Kershaw MH, Beavis PA, Darcy PK.

Cancer Res. 2017 Mar 15;77(6):1296-1309. doi: 10.1158/0008-5472.CAN-16-1831. Epub 2017 Jan 12.

13.

CAR T-cell therapy of solid tumors.

Yong CSM, Dardalhon V, Devaud C, Taylor N, Darcy PK, Kershaw MH.

Immunol Cell Biol. 2017 Apr;95(4):356-363. doi: 10.1038/icb.2016.128. Epub 2016 Dec 22. Review.

PMID:
28003642
14.

Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting.

Slaney CY, von Scheidt B, Davenport AJ, Beavis PA, Westwood JA, Mardiana S, Tscharke DC, Ellis S, Prince HM, Trapani JA, Johnstone RW, Smyth MJ, Teng MW, Ali A, Yu Z, Rosenberg SA, Restifo NP, Neeson P, Darcy PK, Kershaw MH.

Clin Cancer Res. 2017 May 15;23(10):2478-2490. doi: 10.1158/1078-0432.CCR-16-1860. Epub 2016 Dec 13.

15.

A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.

Yong CS, John LB, Devaud C, Prince MH, Johnstone RW, Trapani JA, Darcy PK, Kershaw MH.

Oncotarget. 2016 Jun 7;7(23):34582-98. doi: 10.18632/oncotarget.9149.

16.

Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.

Beavis PA, Slaney CY, Kershaw MH, Gyorki D, Neeson PJ, Darcy PK.

Semin Immunol. 2016 Feb;28(1):64-72. doi: 10.1016/j.smim.2015.11.003. Epub 2015 Nov 25. Review.

PMID:
26611350
17.

CAR-T cells are serial killers.

Davenport AJ, Jenkins MR, Ritchie DS, Prince HM, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ.

Oncoimmunology. 2015 Jun 1;4(12):e1053684. eCollection 2015 Dec.

18.

Expression of a Chimeric Antigen Receptor in Multiple Leukocyte Lineages in Transgenic Mice.

Yong CS, Westwood JA, Schröder J, Papenfuss AT, von Scheidt B, Moeller M, Devaud C, Darcy PK, Kershaw MH.

PLoS One. 2015 Oct 27;10(10):e0140543. doi: 10.1371/journal.pone.0140543. eCollection 2015.

19.

CD73: A potential biomarker for anti-PD-1 therapy.

Beavis PA, Slaney CY, Milenkovski N, Henderson MA, Loi S, Stagg J, Kershaw MH, Darcy PK.

Oncoimmunology. 2015 May 5;4(11):e1046675. eCollection 2015 Nov.

20.

Embryonic Lethality in Homozygous Human Her-2 Transgenic Mice Due to Disruption of the Pds5b Gene.

Yong CS, Sharkey J, Duscio B, Venville B, Wei WZ, Jones RF, Slaney CY, Mir Arnau G, Papenfuss AT, Schröder J, Darcy PK, Kershaw MH.

PLoS One. 2015 Sep 3;10(9):e0136817. doi: 10.1371/journal.pone.0136817. eCollection 2015.

21.

Cross-talk between tumors can affect responses to therapy.

Devaud C, John LB, Westwood JA, Yong CS, Beavis PA, Schwendener RA, Darcy PK, Kershaw MH.

Oncoimmunology. 2015 Jun 17;4(7):e975572. eCollection 2015 Jul.

22.

Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.

Beavis PA, Slaney CY, Kershaw MH, Neeson PJ, Darcy PK.

Immunotherapy. 2015;7(5):499-512. doi: 10.2217/imt.15.16. Review.

PMID:
26065476
23.

Differential potency of regulatory T cell-mediated immunosuppression in kidney tumors compared to subcutaneous tumors.

Devaud C, Westwood JA, Teng MW, John LB, Yong CS, Duong CP, Smyth MJ, Darcy PK, Kershaw MH.

Oncoimmunology. 2014 Dec 21;3(11):e963395. eCollection 2014 Nov.

24.

CAR-T Cells Inflict Sequential Killing of Multiple Tumor Target Cells.

Davenport AJ, Jenkins MR, Cross RS, Yong CS, Prince HM, Ritchie DS, Trapani JA, Kershaw MH, Darcy PK, Neeson PJ.

Cancer Immunol Res. 2015 May;3(5):483-94. doi: 10.1158/2326-6066.CIR-15-0048. Epub 2015 Feb 24. Erratum in: Cancer Immunol Res. 2018 Mar;6(3):370.

25.

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses.

Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK.

Cancer Immunol Res. 2015 May;3(5):506-17. doi: 10.1158/2326-6066.CIR-14-0211. Epub 2015 Feb 11.

26.

The potential impact of mouse model selection in preclinical evaluation of cancer immunotherapy.

Westwood JA, Darcy PK, Kershaw MH.

Oncoimmunology. 2014 Jul 3;3(7):e946361. eCollection 2014.

27.

Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic.

Duong CP, Yong CS, Kershaw MH, Slaney CY, Darcy PK.

Mol Immunol. 2015 Oct;67(2 Pt A):46-57. doi: 10.1016/j.molimm.2014.12.009. Epub 2015 Jan 13. Review.

PMID:
25595028
28.

Clinical application of genetically modified T cells in cancer therapy.

Kershaw MH, Westwood JA, Slaney CY, Darcy PK.

Clin Transl Immunology. 2014 May 16;3(5):e16. doi: 10.1038/cti.2014.7. eCollection 2014 May. Review.

29.

Trafficking of T cells into tumors.

Slaney CY, Kershaw MH, Darcy PK.

Cancer Res. 2014 Dec 15;74(24):7168-74. doi: 10.1158/0008-5472.CAN-14-2458. Epub 2014 Dec 4. Review.

30.

Foxp3 expression in macrophages associated with RENCA tumors in mice.

Devaud C, Yong CS, John LB, Westwood JA, Duong CP, House CM, Denoyer D, Li J, Darcy PK, Kershaw MH.

PLoS One. 2014 Sep 29;9(9):e108670. doi: 10.1371/journal.pone.0108670. eCollection 2014.

31.

Foxp3 expression in T regulatory cells and other cell lineages.

Devaud C, Darcy PK, Kershaw MH.

Cancer Immunol Immunother. 2014 Sep;63(9):869-76. doi: 10.1007/s00262-014-1581-4. Epub 2014 Jul 26. Review.

PMID:
25063364
32.

Combination anti-CD137 and anti-CD40 antibody therapy in murine myc-driven hematological cancers.

Westwood JA, Matthews GM, Shortt J, Faulkner D, Pegram HJ, Duong CP, Chesi M, Bergsagel PL, Sharp LL, Huhn RD, Darcy PK, Johnstone RW, Kershaw MH.

Leuk Res. 2014 Aug;38(8):948-54. doi: 10.1016/j.leukres.2014.05.010. Epub 2014 Jun 2.

PMID:
24934848
33.

Routes of delivery for CpG and anti-CD137 for the treatment of orthotopic kidney tumors in mice.

Westwood JA, Potdevin Hunnam TC, Pegram HJ, Hicks RJ, Darcy PK, Kershaw MH.

PLoS One. 2014 May 2;9(5):e95847. doi: 10.1371/journal.pone.0095847. eCollection 2014.

34.

Environmental enrichment does not impact on tumor growth in mice.

Westwood JA, Darcy PK, Kershaw MH.

F1000Res. 2013 Jun 12;2:140. doi: 10.12688/f1000research.2-140.v1. eCollection 2013.

35.

Manipulating immune cells for adoptive immunotherapy of cancer.

Darcy PK, Neeson P, Yong CS, Kershaw MH.

Curr Opin Immunol. 2014 Apr;27:46-52. doi: 10.1016/j.coi.2014.01.008. Epub 2014 Feb 15. Review.

PMID:
24534448
36.

Blockade of PD-1 immunosuppression boosts CAR T-cell therapy.

John LB, Kershaw MH, Darcy PK.

Oncoimmunology. 2013 Oct 1;2(10):e26286. Epub 2013 Oct 10.

37.

Enhancing immunotherapy using chemotherapy and radiation to modify the tumor microenvironment.

Kershaw MH, Devaud C, John LB, Westwood JA, Darcy PK.

Oncoimmunology. 2013 Sep 1;2(9):e25962. Epub 2013 Aug 2. Review.

38.

Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy.

Devaud C, John LB, Westwood JA, Darcy PK, Kershaw MH.

Oncoimmunology. 2013 Aug 1;2(8):e25961. Epub 2013 Aug 22. Review.

39.

Tissues in different anatomical sites can sculpt and vary the tumor microenvironment to affect responses to therapy.

Devaud C, Westwood JA, John LB, Flynn JK, Paquet-Fifield S, Duong CP, Yong CS, Pegram HJ, Stacker SA, Achen MG, Stewart TJ, Snyder LA, Teng MW, Smyth MJ, Darcy PK, Kershaw MH.

Mol Ther. 2014 Jan;22(1):18-27. doi: 10.1038/mt.2013.219. Epub 2013 Sep 19.

40.

Gene-engineered T cells for cancer therapy.

Kershaw MH, Westwood JA, Darcy PK.

Nat Rev Cancer. 2013 Aug;13(8):525-41. doi: 10.1038/nrc3565. Review.

PMID:
23880905
41.

Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.

John LB, Devaud C, Duong CP, Yong CS, Beavis PA, Haynes NM, Chow MT, Smyth MJ, Kershaw MH, Darcy PK.

Clin Cancer Res. 2013 Oct 15;19(20):5636-46. doi: 10.1158/1078-0432.CCR-13-0458. Epub 2013 Jul 19.

42.

Persistence and efficacy of second generation CAR T cell against the LeY antigen in acute myeloid leukemia.

Ritchie DS, Neeson PJ, Khot A, Peinert S, Tai T, Tainton K, Chen K, Shin M, Wall DM, Hönemann D, Gambell P, Westerman DA, Haurat J, Westwood JA, Scott AM, Kravets L, Dickinson M, Trapani JA, Smyth MJ, Darcy PK, Kershaw MH, Prince HM.

Mol Ther. 2013 Nov;21(11):2122-9. doi: 10.1038/mt.2013.154. Epub 2013 Jul 8.

43.

Immunology. Making macrophages eat cancer.

Kershaw MH, Smyth MJ.

Science. 2013 Jul 5;341(6141):41-2. doi: 10.1126/science.1241716. No abstract available.

PMID:
23828933
44.

Chimeric antigen receptor-redirected T cells display multifunctional capacity and enhanced tumor-specific cytokine secretion upon secondary ligation of chimeric receptor.

Henderson MA, Yong CS, Duong CP, Davenport AJ, John LB, Devaud C, Neeson P, Westwood JA, Darcy PK, Kershaw MH.

Immunotherapy. 2013 Jun;5(6):577-90. doi: 10.2217/imt.13.37.

PMID:
23725282
45.

Engineering T cell function using chimeric antigen receptors identified using a DNA library approach.

Duong CP, Westwood JA, Yong CS, Murphy A, Devaud C, John LB, Darcy PK, Kershaw MH.

PLoS One. 2013 May 7;8(5):e63037. doi: 10.1371/journal.pone.0063037. Print 2013.

46.

A mutant Tat protein provides strong protection from HIV-1 infection in human CD4+ T cells.

Apolloni A, Lin MH, Sivakumaran H, Li D, Kershaw MH, Harrich D.

Hum Gene Ther. 2013 Mar;24(3):270-82. doi: 10.1089/hum.2012.176. Epub 2013 Mar 1.

47.

Virotherapy, gene transfer and immunostimulatory monoclonal antibodies.

Quetglas JI, John LB, Kershaw MH, Alvarez-Vallina L, Melero I, Darcy PK, Smerdou C.

Oncoimmunology. 2012 Nov 1;1(8):1344-1354.

48.

Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer.

John LB, Howland LJ, Flynn JK, West AC, Devaud C, Duong CP, Stewart TJ, Westwood JA, Guo ZS, Bartlett DL, Smyth MJ, Kershaw MH, Darcy PK.

Cancer Res. 2012 Apr 1;72(7):1651-60. doi: 10.1158/0008-5472.CAN-11-2788. Epub 2012 Feb 7.

49.

Immunology. The adjuvant effects of antibodies.

Smyth MJ, Kershaw MH.

Science. 2011 Aug 19;333(6045):944-5. doi: 10.1126/science.1210801. No abstract available.

PMID:
21852479
50.

Autoimmunity associated with immunotherapy of cancer.

Amos SM, Duong CP, Westwood JA, Ritchie DS, Junghans RP, Darcy PK, Kershaw MH.

Blood. 2011 Jul 21;118(3):499-509. doi: 10.1182/blood-2011-01-325266. Epub 2011 Apr 29. Review. Erratum in: Blood. 2012 Dec 20;120(26):5251.

PMID:
21531979

Supplemental Content

Loading ...
Support Center